Halozyme Therapeutics, Inc. (HALO)

Last Closing Price: 95.80 (2026-11-18)

EBIT (Quarterly)

EBIT: Income before interest and taxes.

Halozyme Therapeutics, Inc. (HALO) had EBIT of $294.97M for the most recently reported fiscal quarter, ending 2026-09-30.

Figures for fiscal quarter ending 2026-09-30
Income Statement Financials
$492.97M
$247.05M
$82.47M
$410.50M
$198.00M
$294.97M
$-4.34M
$290.63M
$290.63M
$247.05M
$247.05M
$247.05M
$247.05M
EBIT
$294.97M
$330.84M
113.80M
122.61M
$2.17
$2.01
Balance Sheet Financials
$1.85B
$82.29M
$1.63B
$3.47B
$476.09M
$2.94B
$3.05B
$3.53B
$-55.24M
$-1.53B
$-55.24M
113.94M
Cash Flow Statement Financials
$679.24M
$-44.59M
$259.78M
$136.42M
$1.03B
$894.43M
$51.14M
--
--
Fundamental Metrics & Ratios
3.88
--
--
1.02
-58.84
83.27%
59.83%
59.83%
--
58.95%
50.11%
$668.27M
--
--
--
0.14
0.62
0.94
95.95
-447.24%
-16.15%
7.11%
8.55%
$-0.48
$5.45
$5.54